STOCK TITAN
  1. Home
  2. Sec-filings
  3. VIR
  4. [Form 4] Vir Biotechnology, Inc. Insider Trading Activity

Vir Biotechnology Form 4: 10b5‑1 sales total 330,210 shares

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Vir Biotechnology (VIR) insider filing shows affiliated entities of SoftBank reported open‑market sales of common stock. SVF Endurance (Cayman) Limited sold 220,535 shares on 10/20/2025 at a weighted average price of $6.1998 and sold 109,675 shares on 10/21/2025 at a weighted average price of $6.3002. The transactions were effected pursuant to a Rule 10b5‑1 trading plan entered on September 3, 2025.

Following these sales, the reporting persons showed indirect beneficial ownership of 15,119,959 shares after the 10/20/2025 trades and 15,010,284 shares after the 10/21/2025 trades, held through SVF Endurance (Cayman) Limited as described in the footnotes.

Positive

  • None.

Negative

  • None.
Insider SVF Endurance (Cayman) Ltd, SOFTBANK VISION FUND (AIV M1) L.P., SB INVESTMENT ADVISERS (UK) LTD
Role 10% Owner | 10% Owner | 10% Owner
Sold 330,210 shs ($2.06M)
Type Security Shares Price Value
Sale Common Stock 109,675 $6.3002 $691K
Sale Common Stock 220,535 $6.1998 $1.37M
Holdings After Transaction: Common Stock — 15,010,284 shares (Indirect, See footnote)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.2961. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.4406. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd
(Last) (First) (Middle)
C/O WALKERS CORP LTD.,
190 ELGIN AVENUE
(Street)
GEORGE TOWN E9 KY1-9008
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Vir Biotechnology, Inc. [ VIR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
X Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/20/2025 S(1) 220,535 D $6.1998(2) 15,119,959 I See footnote(3)
Common Stock 10/21/2025 S(1) 109,675 D $6.3002(4) 15,010,284 I See footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
1. Name and Address of Reporting Person*
SVF Endurance (Cayman) Ltd
(Last) (First) (Middle)
C/O WALKERS CORP LTD.,
190 ELGIN AVENUE
(Street)
GEORGE TOWN E9 KY1-9008
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SOFTBANK VISION FUND (AIV M1) L.P.
(Last) (First) (Middle)
1521 CONCORD PIKE
(Street)
WILMINGTON, DE 19803
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
1. Name and Address of Reporting Person*
SB INVESTMENT ADVISERS (UK) LTD
(Last) (First) (Middle)
69 GROSVENOR STREET
(Street)
LONDON, X0 W1K 3JP
(City) (State) (Zip)
Relationship of Reporting Person(s) to Issuer
Director X 10% Owner
Officer (give title below) Other (specify below)
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.2961. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.4406. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
SVF Endurance (Cayman) Limited, By: /s/ Nilani Perera, Director 10/22/2025
SoftBank Vision Fund (AIV M1) L.P., By: SB Investment Advisers (UK) Limited, its manager, By: /s/ Amanda Sanchez-Barry, General Counsel 10/22/2025
SB Investment Advisers (UK) Limited, By: /s/ Amanda Sanchez-Barry, General Counsel 10/22/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did VIR insiders report selling in this Form 4?

SVF Endurance (Cayman) Limited reported selling 220,535 shares on 10/20/2025 and 109,675 shares on 10/21/2025 of Vir Biotechnology common stock.

At what prices were the VIR shares sold?

Weighted average prices were $6.1998 on 10/20/2025 and $6.3002 on 10/21/2025. Footnotes note ranges of $6.07–$6.2961 and $6.12–$6.4406, respectively.

Were the VIR share sales under a 10b5-1 plan?

Yes. The filing states the sales were made under a Rule 10b5‑1 trading plan entered on September 3, 2025.

How many VIR shares were beneficially owned after the transactions?

Indirect beneficial ownership was 15,119,959 shares after 10/20/2025 trades and 15,010,284 shares after 10/21/2025 trades.

Who is the reporting holder for these VIR shares?

The record holder is SVF Endurance (Cayman) Limited, a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. as described in the footnotes.

How can exact trade breakdowns be obtained?

The filing states the reporting persons will provide the number of shares sold at each price within the disclosed ranges upon request.